Why the study?
Is the apoE4 phenotype associated with type V hyperlipoproteinemia?
Is the apoE4 phenotype associated with type V hyperlipoproteinemia?
The apoE4 phenotype is significantly more frequent in patients with type V hyperlipoproteinemia, suggesting its involvement in the development of this lipid disorder.
ApoE4 association with type V hyperlipoproteinemia is hypothesis-generating; prospective studies required before any clinical screening or risk stratification.
Type V hyperlipoproteinemia is characterized by elevations of chylomicron (CM) and very low density lipoprotein (VLDL) triglycerides. The development of this lipid disorder involves a multitude of metabolic derangements including deficient clearance of triglycerides and/or their increased output aggravated by obesity, diabetes, alcohol intake, or use of some hormones. Some studies have suggested that the apolipoprotein E4 phenotype is involved in this dyslipoproteinemia but this concept is still a matter of controversy. Therefore, we determined the apoE phenotype in 21 patients with severe hypertriglyceridemia classified as type V. Their apoE4 gene frequency was 0.595 which is 2.6-fold higher (P less than 0.001) than that in the Finnish population. Correspondingly, their apoE3 gene frequency was lower than that in the normal population. No differences were noted in plasma lipoproteins of the apoE4 phenotypes and the other type V subjects. The apolipoprotein C-II and C-III distribution was similar to that in normolipidemic subjects. The results suggest that apoE4 may be involved in the development of type V hyperlipoproteinemia.
No takes yet. Share an insight, caveat, or question.
Kuusi et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: